Scaled Variable Importance Projection Scores and Individual Diagnostic Performance of the Top 12 Contributing Analytes
| Cytokine/Chemokine . | Variable Importance Projection Score . | Univariate AUC (95% CI) . |
|---|---|---|
| CCL2 | 100 | 0.71 (.59–.83) |
| IL-12p70 | 44.1 | 0.59 (.46–.72) |
| IL-1α | 42.3 | 0.59 (.46–.73) |
| IL-1β | 37.9 | 0.56 (.42–.69) |
| CCL4 | 31.3 | 0.60 (.46–.73) |
| IL-1RN | 27.8 | 0.60 (.46–.74) |
| CXCL8 | 21.1 | 0.54 (.41–.68) |
| CXCL10 | 9.6 | 0.50 (.37–.64) |
| IL-17A | 7.3 | 0.53 (.42–.64) |
| CXCL9 | 4.4 | 0.51 (.37–.64) |
| CCL20 | 3.8 | 0.51 (.37–.62) |
| CCL3 | 0 | 0.49 (.36–.63) |
| Cytokine/Chemokine . | Variable Importance Projection Score . | Univariate AUC (95% CI) . |
|---|---|---|
| CCL2 | 100 | 0.71 (.59–.83) |
| IL-12p70 | 44.1 | 0.59 (.46–.72) |
| IL-1α | 42.3 | 0.59 (.46–.73) |
| IL-1β | 37.9 | 0.56 (.42–.69) |
| CCL4 | 31.3 | 0.60 (.46–.73) |
| IL-1RN | 27.8 | 0.60 (.46–.74) |
| CXCL8 | 21.1 | 0.54 (.41–.68) |
| CXCL10 | 9.6 | 0.50 (.37–.64) |
| IL-17A | 7.3 | 0.53 (.42–.64) |
| CXCL9 | 4.4 | 0.51 (.37–.64) |
| CCL20 | 3.8 | 0.51 (.37–.62) |
| CCL3 | 0 | 0.49 (.36–.63) |
Variable importance projection scores indicated that CCL2 was the most important cytokine to differentiate between phases.
Abbreviations: AUC, area under the curve; CI, confidence interval; IL-1RN, interleukin 1 receptor antagonist; IL-1α, interleukin 1α; IL-1β, interleukin 1β; IL-12p70, interleukin 12p70; IL-17A, interleukin 17A.
Scaled Variable Importance Projection Scores and Individual Diagnostic Performance of the Top 12 Contributing Analytes
| Cytokine/Chemokine . | Variable Importance Projection Score . | Univariate AUC (95% CI) . |
|---|---|---|
| CCL2 | 100 | 0.71 (.59–.83) |
| IL-12p70 | 44.1 | 0.59 (.46–.72) |
| IL-1α | 42.3 | 0.59 (.46–.73) |
| IL-1β | 37.9 | 0.56 (.42–.69) |
| CCL4 | 31.3 | 0.60 (.46–.73) |
| IL-1RN | 27.8 | 0.60 (.46–.74) |
| CXCL8 | 21.1 | 0.54 (.41–.68) |
| CXCL10 | 9.6 | 0.50 (.37–.64) |
| IL-17A | 7.3 | 0.53 (.42–.64) |
| CXCL9 | 4.4 | 0.51 (.37–.64) |
| CCL20 | 3.8 | 0.51 (.37–.62) |
| CCL3 | 0 | 0.49 (.36–.63) |
| Cytokine/Chemokine . | Variable Importance Projection Score . | Univariate AUC (95% CI) . |
|---|---|---|
| CCL2 | 100 | 0.71 (.59–.83) |
| IL-12p70 | 44.1 | 0.59 (.46–.72) |
| IL-1α | 42.3 | 0.59 (.46–.73) |
| IL-1β | 37.9 | 0.56 (.42–.69) |
| CCL4 | 31.3 | 0.60 (.46–.73) |
| IL-1RN | 27.8 | 0.60 (.46–.74) |
| CXCL8 | 21.1 | 0.54 (.41–.68) |
| CXCL10 | 9.6 | 0.50 (.37–.64) |
| IL-17A | 7.3 | 0.53 (.42–.64) |
| CXCL9 | 4.4 | 0.51 (.37–.64) |
| CCL20 | 3.8 | 0.51 (.37–.62) |
| CCL3 | 0 | 0.49 (.36–.63) |
Variable importance projection scores indicated that CCL2 was the most important cytokine to differentiate between phases.
Abbreviations: AUC, area under the curve; CI, confidence interval; IL-1RN, interleukin 1 receptor antagonist; IL-1α, interleukin 1α; IL-1β, interleukin 1β; IL-12p70, interleukin 12p70; IL-17A, interleukin 17A.
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
